UK markets open in 2 hours 39 minutes

NIKKEI 225
37,710.95
-749.13(-1.95%)
HANG SENG
17,295.93
+94.66(+0.55%)
CRUDE OIL
82.90
+0.09(+0.11%)
GOLD FUTURES
2,326.10
-12.30(-0.53%)
DOW
38,460.92
-42.77(-0.11%)
Bitcoin GBP
51,469.16
-2,040.62(-3.81%)

The five essential pieces of financial paperwork you must never lose

Mislaying key documents can cause real headaches, so it’s worth tracking down these most commonly-lost bits of paperwork

NovoCure Limited (038.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR

Add to watchlist

11.21

-0.22

(-1.92%)

At close: 03:52PM CEST

All

Business Wire
Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024
ROOT, Switzerland, April 24, 2024--Novocure (NASDAQ: NVCR) today announced the results of the METIS phase 3 clinical trial in brain metastases from non-small cell lung cancer (NSCLC) will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, to be held from May 31 to June 4.
Business Wire
Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024
ROOT, Switzerland, April 05, 2024--Novocure (NASDAQ: NVCR) today announced 20 presentations on Tumor Treating Fields (TTFields) therapy will be delivered at the American Association for Cancer Research (AACR) Annual Meeting 2024, to be held April 5 to 10 in San Diego.
Zacks
NovoCure (NVCR) Moves to Buy: Rationale Behind the Upgrade
NovoCure (NVCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).